HES1 Protein Modulates Human Papillomavirus–Mediated Carcinoma of the Uterine Cervix

Richa Tripathi, PhD; Gayatri Rath, MS; Vishwas Sharma, PhD; Showket Hussain, PhD; Shashi Sharma, PhD; Mausumi Bharadwaj, PhD; and Ravi Mehrotra, MD

abstract

PURPOSE Cervical cancer (CC) is the most common cancer affecting women worldwide. Human papillomavirus (HPV) infection is a major contributing factor for the development of CC. The development of CC occurs progressively from precancer stages to cancerous stages (ie, invasive squamous cell carcinoma [ISCC] and adenocarcinoma [ADC]). ADC is a rare form of CC that develops from the mucinous endocervical epithelium. It is believed that the downstream targets of Notch signaling contribute to the etiology of CC. One such target is HES1, whose role in the modulation of ADC is unknown. The purpose of this study is to determine the role of HES1 protein in HPV-associated ADC subtype of CC and also to compare its expression in histologic subtypes of precancer and ISCC.

PATIENTS AND METHODS A total of 148 patients (30 with precancers, 98 with ISCC, and 20 with ADC) and 40 normal control participants were analyzed for the expression of HES1 via immunohistochemistry, with results validated by immunoblotting.

RESULTS The comparison between HPV-16 and HES1 expression was significant in precancer (cervical intraepithelial neoplasia grades 1 to 3; \( P = .013 \)), ISCC (International Federation of Gynecology and Obstetrics stages I to IV; \( P = .001 \)), and ADC (\( P = .007 \)). An overall significant mean difference was observed between HES1, JAG1, and Notch-3 proteins in precancer (\( P = .001 \)), ISCC (\( P = .001 \)), and ADC (\( P = .001 \)). Pairwise comparisons between HES1 and JAG1 and HES1 and Notch-3 were also found to be significant.

CONCLUSION This study showed that among all HPV-16–positive precancers, the major HES1 positivity signal arises from cervical intraepithelial neoplasia grades 2 and 3 that develops into ISCC. Moreover, HPV-16–positive ADC also showed an association with HES1. The HES1, JAG1, and Notch-3 proteins showed their synergistic role in modulating HPV associated ADC along with histologic subtypes of precancer and ISCC of CC.

INTRODUCTION

Hairy and enhancer of split homolog-1 (HES1) is a downstream effector target for mammalian Notch signaling pathway.\(^1\) The Hes family comprises seven members, Hes1 to Hes7, all of which are structurally conserved and broadly classified into two groups based on their regulation by Notch.\(^1\) The active form of Notch activates the promoter of Hes1, which affects its expression and is believed to inhibit cell differentiation and promote the survival of stem cells.\(^2,3\) The over-activation of HES1 is believed to influence the balance between cell proliferation and differentiation.\(^4\) Liu et al\(^5\) demonstrated a role of HES1 in cancer stem cells, metastasis, and cell fate. It has also been shown that HES1 promotes cell proliferation in cervical cancer (CC) and thus may be involved in carcinogenesis of the cervix and progression of CC.\(^1,6\) CC ranks fourth among female-related cancers worldwide, with a reported incidence of approximately 528,000 new cancers every year.\(^7\) In India, its incidence rate is 122,844 cancers per year, and CC is reported to be the second most common cancer affecting women age 15 to 44 years.\(^8\) Infection with high-risk subtypes of human papillomavirus (HPV; types 16 and 18) plays a preponderant role in the development of precancer of the uterine cervix (UC) and the majority of CC subtypes. High-risk HPV encodes multifunctional growth-promoting E6 and E7 oncoproteins that bind and inactivate tumor suppressor genes. In HPV-infected cells, a complex network of protein interactions has been reported with other key signaling pathways such as Notch, TGFβ/SMAD, and WNT/β-catenin.\(^9\) However, the altered molecular mechanisms responsible for activation of various pathways leading to CC remain unknown.
Histologically, precancer of UC is classified by the Bethesda System into squamous intraepithelial lesion subtypes or cervical intraepithelial neoplasia (CIN; grades 1 to 3). Low-grade squamous intraepithelial lesions include mild dysplasia or CIN 1; high-grade squamous intraepithelial lesions include moderate dysplasia or CIN 2; and severe dysplasia includes carcinoma in situ or CIN 3. Similarly, cancer of UC is divided into invasive squamous cell carcinoma (ISCC) and adenocarcinoma (ADC). CC is classified by the International Federation of Gynecology and Obstetrics (FIGO) system according to the clinical and/or pathologic spread of disease. ISCC is the most common type of CC, composing 85% to 90% of CCs in India. ADC, a rare subtype, develops from the mucinous endocervical epithelium (mucus-producing gland cells) and is classified as either ADC in situ (precursor lesion) or invasive ADC. It is generally difficult to diagnose ADC in situ because pathologists cannot use the basement membrane for the measurement of invasion. ADC of UC has chemotherapy- and radiotherapy-resistant properties; therefore, the response to bevacizumab plus paclitaxel and cisplatin therapy, which is a gold standard therapy for ISCC, is not significant in ADC. Unlike squamous cell carcinoma, the prevalence of ADC is increasing worldwide at an alarming rate. However, in India, it composes 10% to 15% of CCs. Moreover, in North India, it is rare for patients with ADC to visit hospitals; therefore, treating these patients is a challenging task. In addition, the majority of patients with CC report to hospitals at late stages, and therefore, diagnosis of patients with CC occurs at late stages, underscoring the need to improve early diagnosis and treatment via targeted therapies among women. To do this, we must understand the molecular mechanisms of the disease. To our knowledge, there is no study available to date regarding the molecular mechanisms of ADC of CC (Data Supplement). However, with respect to precancer and ISCC of UC, only four studies are available suggesting that HES1 may drive tumorogenesis inducing neoplastic transformation. Therefore, this study aims to fill the research gap by studying the role of HES1 expression in HPV-associated ADC, as well as in precancer and ISCC of CC. This will help us to clarify the role of HES1 in the progression of this neoplastic disease.

**PATIENTS AND METHODS**

**Study Design and Participants**

A total of 148 patients (30 with precancers, 98 with ISCC, and 20 with ADCs) and 40 normal control participants (ultraviolet prolapse, nonneoplastic tissues) were enrolled from the Department of Obstetrics and Gynecology of the Safdarjang Hospital in New Delhi, India. Approval was provided by the Research and Ethics Committee of the National Institute of Cancer Prevention and Research—Indian Council of Medical Research in Noida, India, and Vardhman Mahavir Medical College and Safdarjang Hospital in New Delhi, India. All untreated individuals enrolled onto the study with no family history of CC provided written informed consent. Patients with precancers included 19 with CIN 1, three with CIN 2, and eight with CIN 3. The clinical staging of tumors was confirmed according to the FIGO classification criteria of tumor staging along with its respective histopathologic grade by two independent pathologists. Among ISCCs (n = 98), 33 were FIGO stage I or II and 65 were FIGO stage III or IV. All of the collected ADC samples were invasive ADC and pathologic grade 2 or 3 and FIGO stage III or IV. All patients were diagnosed by colposcopic biopsy; however, ADCs were more difficult to diagnose than ISCCs. In addition, all biopsy samples were used for molecular investigations.

All data generated or analyzed during this study are included in this published article and its Data Supplement. The raw data files used in the article can be provided upon request.

**Immunohistochemistry**

Formalin-fixed paraffin-embedded specimens were processed for fine sections (5 μm) and were mounted on slides coated with poly-L-lysine (Sigma, St Louis, MO), followed by conventional hematoxylin and eosin staining for histologic assessment and immunohistochemistry (IHC). Citrate buffer (pH 6.0) was used for antigen retrieval treatment in the microwave and incubated overnight at 4°C with the primary rabbit polyclonal antibody of HES1 (ab87395; Abcam, Cambridge, United Kingdom) at a dilution of 1:250 respectively. An Envision System peroxidase kit (DAKO, Carpinteria, CA) was used for staining. Detailed methodology has been described earlier.

**Scoring of IHC**

IHC results for HES1 protein followed the scoring criteria provided by Tripathi et al. A total score was obtained by adding the percent positivity and intensity scores.

**Immunoblotting**

Immunoblotting from all cervical tissues was done according to a previous study from our laboratory. Polyclonal antihuman antibodies of HES1, β-actin (rabbit monoclonal β-actin antibody 1:2,000; Abcam), and diluted secondary antibody horseradish peroxidase–conjugated rabbit anti-IgG (Abcam) were used in this study. The expression levels of HES1 in tumor tissues were quantitated and compared with their expression levels in normal tissues and were evaluated by densitometry using Alpha Digidoc version 4.1.0 (Alpha Innotech, San Leandro, CA), as described in our previous report.
because of their limited numbers and their higher pathologic grade (2 and 3) and FIGO stage (III and IV). The analysis of HES1 protein expression in patients with precancer, ISCC, and ADC, along with their correlation with HPV subtypes was evaluated using the χ² test. The non-parametric Kruskal-Wallis test was applied for comparison of HES1, JAG1, and Notch-3 because the data were not normally distributed. The overall mean differences between these proteins and pairwise comparisons were performed using the Mann-Whitney U test between groups, as follows: HES1 and JAG1, HES1 and Notch-3, and JAG1 and Notch-3. SPSS (version 20; SPSS, Chicago, IL) statistical software was used for all analysis. \( P \leq .05 \) was considered significant.

**RESULTS**

**Correlation of HES1 Expression in HPV-Infected Precancers, ISCCs, and ADCs**

**Precancer.** The comparison between HPV-negative or -positive status and HES1 expression was found to be nonsignificant (\( P = .154 \)) in CIN 1 (Table 1). However, in patients with CIN 2 and 3, it was found to be significant (\( P = .011 \)). In addition, the comparison between HPV-negative or HPV-positive status and HES1 expression in all patients with CIN 2 and 3. However, none of the patients with precancer were found to be infected with HPV-18; therefore, this comparison was not done.

**ISCC.** The comparison between HPV-negative or -positive status and HES1 expression in less invasive ISCC (FIGO stage I or II) was found to be significant (\( P = .034 \)). Similarly, this comparison was also found to be significant in patients with highly invasive ISCC (FIGO stage III or IV; \( P = .023 \)) and in all patients with ISCC (FIGO stage I to IV; \( P = .001 \); Table 2). This signifies that the majority of HES1 expression came from HPV-16–positive CIN 2 and 3 and was also found to be intensified in all ISCCs.

Therefore, in patients with ISCC, HPV-16 was found to be significantly linked with HES1 expression in all subgroups. However, we did not find a significant association between HPV-18 and HES1, which could be a result of the small number of HPV-18–positive patients.

**ADC.** A significant association between HES1 (\( P = .007 \)) and HPV-16–positive ADC was observed (Table 2). Only 1 of 20 patients was infected with HPV-18 and found to be HES1 positive (\( P = .666 \); Table 2).

The overall results suggest the hypothesis that the altered HES1 plays a regulating role in precancer, ISCC, and ADC by synergizing with HPV-16 as the aggressiveness of the tumor increases. The increased expression level of this protein in the nucleus suggests its association with bHLH protein and regulation of its own expression through a negative feedback loop and, subsequently, suppression of the transcription of various genes that influence cell proliferation and differentiation (Fig 1).

**Expression Profile of HES1 Protein in Precancer, ISCC, and ADC Lesions of the Human Cervix by IHC**

The expression profile (Fig 2A to Fig 2G) and total expression scores (Table 3) of HES1 in the nucleus were determined in normal, precancer, ISCC, and ADC tissues. An approximate four-fold increase (mean \( \pm SE \), 2.43 \( \pm \) 0.30; \( P < .001 \)) in nuclear HES1 expression was identified in normal versus precancer tissue, a seven-fold increase (mean \( \pm SE \), 3.76 \( \pm \) 0.21; \( P < .001 \)) was observed in normal versus ISCC tissue, and an eight-fold increase (mean \( \pm SE \), 4.75 \( \pm \) 0.50; \( P < .001 \)) was observed in normal versus ADC tissue. Among patients with precancer (CIN 1 and CIN 2 and 3), HES1 expression is provided in the Data Supplement. The expression of HES1 in two ISCC subcategories is also provided in the Data Supplement. Figure 2H shows total IHC HES1 expression scores in normal cervix, precancer, ISCC, and ADC biopsies. Hence, an overall gradual increase in HES1 expression was observed in moving from precancer to ISCC and ADC.

**Combined Impact of HES1 and JAG1 or HES1 and Notch-3 Expression on Precancer, ISCC, and ADC**

We analyzed the combined effect of HES1 and JAG1 and of HES1 and Notch-3 on precancers, ISCC, and ADC (Table 3 and Data Supplement). For this purpose, we used the JAG1 data from precancers, ISCC, and ADC from our previous report; Notch-3 precancer and ISCC data from our previously published study; and ADC data from our unpublished records (IHC figures available upon request). An overall significant mean difference was determined between HES1, JAG1, and Notch-3 proteins in precancer (\( P = .001 \)), ISCC (\( P = .001 \)), and ADC (\( P = .001 \)).

Pairwise comparisons between HES1 and JAG1 and between HES1 and Notch-3 were also found to be statistically significant in precancer, ISCC, and ADC. This fact implies that all of these proteins should be studied concomitantly in the future to understand the complex cascade of events modulating precancer, ISCC, and ADC.

**Receiver Operating Characteristic Curve Analysis: Potential Determination of HES1 Expression to Distinguish Precancer, ISCC, and ADC From Normal Cervical Tissue**

The area under the curve (AUC) values for nuclear HES1 in precancer (AUC, 0.80; \( P < .001 \)), ISCC (AUC, 0.88; \( P < .001 \)), and ADC (AUC, 0.90; \( P < .001 \)) were determined (Fig 3 and Data Supplement). The sensitivity and specificity for nuclear HES1 in precancer, ISCC, and ADC were 73.30% and 89.80%, 86.7% and 75%, and 85% and 75%, respectively. High sensitivity and specificity of HES1
Table 1. Correlation of HES1 Expression in HPV-Infected Patients With Precancer (CIN 1, 2, or 3)

| HPV Status | CIN 1          |                     |                     | CIN 2 and 3      |                     |                     | CIN 1, 2, or 3      |                     |                     |
|------------|----------------|---------------------|---------------------|------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|            | HES1 Status (No. of Patients [%]) |                     |                     | HES1 Status (No. of Patients [%]) |                     |                     | HES1 Status (No. of Patients [%]) |                     |                     |
| HPV-16     | No. of Patients | Negative            | Positive            | P                 | No. of Patients | Negative            | Positive            | P                 | No. of Patients | Negative            | Positive            | P                 |
|            |                | 3                   | 2 (66.6)            | 1 (33.3)          | 6                   | 2 (66.6)            | 1 (33.3)          | 0.154              | 24                  | 4 (16.6)            | 20 (83.3)           | 0.013              |
| Negative   | 3              | 2 (66.6)            | 1 (33.3)            | 0.154             | 6                   | 2 (66.6)            | 1 (33.3)          | 0.011              | 24                  | 4 (16.6)            | 20 (83.3)           | 0.013              |
| Positive   | 16             | 4 (25)              | 12 (75)             | 0.154             | 8                   | 0 (0)               | 8 (100)            | 0.011              | 24                  | 4 (16.6)            | 20 (83.3)           | 0.013              |
| HPV-18     |                | —                   | —                   | —                 | —                   | —                   | —                   | —                 | —                   | —                   | —                   | —                 |
| Negative   | 19             | 6 (31.5)            | 13 (68.4)           | —                 | 11                  | 2 (18.1)            | 9 (81.8)           | 0.134              | 30                  | 8 (26.6)            | 22 (73.3)           | 0.134              |
| Positive   | 0              | —                   | —                   | —                 | 0                   | 0 (0)               | 0 (0)              | —                 | 0                   | 0 (0)               | —                   | —                 |

Abbreviations: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.
| HPV Status | No. of Patients | Negative | Positive | P  | No. of Patients | Negative | Positive | P  | No. of Patients | Negative | Positive | P  | No. of Patients | Negative | Positive | P  |
|------------|----------------|----------|----------|----|----------------|----------|----------|----|----------------|----------|----------|----|----------------|----------|----------|----|
| HPV-16     |                |          |          |    |                |          |          |    |                |          |          |    |                |          |          |    |
| Negative   | 9              | 04 (44.4)| 05 (55.5)| .034 | 7              | 03 (42.8)| 04 (57.1)| .023 | 16             | 07 (43.7)| 09 (56.2)| .001| 3              | 02 (66.7)| 01 (33.3)| .007 |
| Positive   | 24             | 02 (8.3)| 22 (91.6)| .665 | 58             | 04 (6.8)| 54 (93.1)| .627 | 82             | 06 (7.3)| 76 (92.6)| .415| 17             | 01 (5.9)| 16 (94.1)| .666 |
| HPV-18     |                |          |          |    |                |          |          |    |                |          |          |    |                |          |          |    |
| Negative   | 31             | 06 (19.3)| 25 (80.6)| .19 | 61             | 07 (11.4)| 54 (88.5)| .19 | 92             | 13 (14.1)| 79 (85.8)| .19 | 19             | 03 (15.8)| 16 (84.2)| .19 |
| Positive   | 2              | 00 (0)  | 02 (100) | .00 | 4              | 00 (0)  | 02 (100) | .00 | 6              | 00 (0)  | 06 (100) | .00 | 1              | 00 (0)  | 1 (100)  | .00 |

Abbreviations: ADC, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; ISCC, invasive squamous cell carcinoma.
in precancer, ISCC, and ADC support the clinical utility of HES1 for early detection and progression of CC.

**Clinicopathologic Parameters of ISCC and IHC Expression of HES1**

The clinicopathologic parameters of ISCC showed association with HES1 expression as follows (Data Supplement). HES1 was found to be associated with tobacco (88.9%; \( P = .04 \)), tumor size (90.2%; \( P < .001 \)), tumor vaginal involvement (89.2%; \( P < .001 \)), lymph node metastasis (87.7%; \( P < .002 \)), and FIGO stage (89.2%; \( P < .001 \)). These results imply the pathogenic aggressiveness of CC when associated with HES1.

**Immunoblotting**

A gradual increase in the expression of HES1 (30 kDa) identified via immunoblotting in precancer, ISCC, and ADC samples (Fig 2) validates the findings of IHC.

**DISCUSSION**

A growing understanding of the complex signaling pathways that underlie progression of a tumor is driving the development of new therapeutic targets at specific molecular events. Currently, there is no targeted therapy available for CC because the molecular mechanisms underlying CC development and progression remain poorly defined. Evidence suggests that HPV infection alone is inadequate to induce malignant changes and that altered signaling pathways are also important for the development of CC. It was hypothesized that activated Notch-3 and JAG1 interact synergistically with HPV oncoproteins E6 and E7 and induce the Notch signaling pathway, promoting cell proliferation and tumorigenesis.\(^{19,21}\) HES1 was reported to be a Notch-targeted gene by showing suppression of Notch signaling–mediated gene expression by DN-MAML expression, leading to decrease of HES1.\(^{22}\)

This study compared HES1 expression in HPV-negative and -positive patients with precancer (CIN 1, CIN 2 and 3), ISCC (FIGO stage I and II, and III and IV), and ADC and suggests that, among all patients HPV-16–positive precancers, the major HES1 positivity signal arises from CIN 2 and 3 precancers that develop into ISCC. Moreover, HPV-16–positive patients with invasive ADC also showed an association with HES1.

The expression of HES1 in precancer, ISCC, and ADC of UC was found to be significantly upregulated progressively as compared with normal cervix tissue. This implies an increasing trend of HES1 expression from HPV-16–positive precancer to ISCC and ADC. This hypothesis was supported by Liu et al\(^{6}\) in 2010; however, it needs to be
explored further. Our results are in concordance with previous studies in which the upregulation of HES1 both at the RNA and protein levels was identified but only in precancer and ISCC. Briefly, Liu et al found higher expression of HES1 only in CIN lesions, and no difference was found in ISCC. However, Ramdass et al observed elevated expression in ISCC but only through IHC. The present study extends the previous findings by adding the knowledge of HES1 upregulated expression in HPV-infected ADC (rare subtype of CC) and compared the expression in HPV-associated precancer, HPV-associated ISCC, and HPV-associated ADC. In addition, we have extended our work with respect to validation of IHC results by Western blotting. Rong et al also investigated HES1 at the RNA level by quantitative reverse transcription polymerase chain reaction and observed similar increased expression levels in CC tissues.

A combined impact and significant mean difference of HES1 and JAG1 and of HES1 and Notch-3 were observed in precancer, ISCC, and ADC. Hence, HES1, JAG1, and Notch-3 are interrelated with each other. This confirms that HES1 is an effector target of triggered activation of JAG1-induced Notch signaling, which could be of potential diagnostic utility in early- and late-stage patients with CC. Hence, the previously observed activated Notch pathway, in turn, alters HES1 progressively in the modulation of CC cell proliferation.

High sensitivity and specificity of nuclear HES1 in precancer, ISCC, and ADC strongly support its clinical significance for early detection, progression, and monitoring of patients with cervical dysplasia. An association between clinicopathologic parameters of patients with ISCC and nuclear HES1 was observed with respect to tumor size, tumor vaginal invasion, FIGO stage, and lymph node metastasis, suggesting the contribution of HES1 to progression, aggressiveness, and invasion of tumor, thereby showing its potential clinical utility as a candidate predictive marker for CC.

To improve patient care with targeted therapies that lead to more accuracy and specificity, the combined analysis of HES1, JAG1, and Notch-3 in ADC is required. This pilot study on ADC is a step toward understanding the role of HES1 in the HPV-16–induced Notch signaling pathway in the rare ADC subtype of CC. Hence, this report may be a torchbearer for researchers and clinicians to understand the involvement of Notch signaling in regulating molecular alterations of HES1 in HPV-associated precancer, ISCC, and ADC. Using HES1 as a targeted therapy in combination with other chemotherapeutics drugs may be a novel approach to abolish or

---

**FIG 2.** Expression analysis of HES1 in normal, precancer, invasive squamous cell carcinoma (ISCC), and adenocarcinoma (ADC) tissues of uterine cervix (UC). Immunohistochemical analysis showed (A) negative control in normal tissue (magnification, ×200); (B) no nuclear expression of HES1 in normal cervix (×200); (C) mild nuclear expression of HES1 in precancer (×200); (D) negative control in ISCC tissue (×200); (E) moderate nuclear expression of HES1 in ISCC (×200); (F) negative control in ADC (×200); and (G) intense nuclear localization of HES1 in ADC (×200). (H) Bar graph showing expression of HES1 in normal, precancer, ISCC, and ADC samples. (I) Western blots depict the expression of HES1 in normal (N), precancer (P), ISCC, and ADC tissues.
| Protein | Normal (n = 40) | Precancer (n = 30) | ISCC (n = 98) | ADC (n = 20) |
|---------|----------------|-------------------|---------------|--------------|
|         | Mean Score | SE    | SD     | Mean Score | SE    | SD     | Median | P*       | P†       | Mean Score | SE    | SD     | Median | P*       | P†       | Mean Score | SE    | SD     | Median | P*       | P†       |
| HES1    | 0.53       | 0.14   | 0.93   | 2.43       | 0.30   | 1.67   | 3.0 | < .001   |          | 3.76       | 0.21   | 2.10   | 4.0 | .001      | < .001   | 4.75       | 0.50   | 2.25   | 6.0 | .001      | < .001   |
| JAG1    | 0.95       | 0.21   | 1.35   | 3.70       | 0.38   | 2.10   | 4.0 | < .001   |          | 4.64       | 0.16   | 1.68   | 5.0 | < .001     |          | 4.20       | 0.40   | 1.80   | 5.0 | < .001     |          |
| Notch-3 | 0.70       | 0.20   | 1.30   | 4.17       | 0.39   | 2.18   | 5.0 | < .001   |          | 4.74       | 0.18   | 1.82   | 6.0 | < .001     |          | 1.20       | 0.49   | 2.12   | 6.0 | < .001     |          |

Abbreviations: ADC, adenocarcinoma; ISCC, invasive squamous cell carcinoma; SD, standard deviation.
*The overall significant mean difference between HES1, JAG1, and Notch-3 proteins using Kruskal-Wallis test.
†The comparison of mean scores between normal versus precancer, normal versus ISCC, and normal versus ADC independently in HES1, JAG1, and Notch-3 via χ² test.
manage this deadly neoplastic phenotype to improve survival times in patients with ISCC and ADC. However, future studies need to be done in a large cohort of patients with ADC (both ADC in situ and invasive ADC) to confirm our findings. This study may help in designing future studies, understanding the molecular mechanism modulating CC, and targeting HES1 via molecular therapeutics.

**AFFILIATIONS**

1Indian Council of Medical Research–National Institute of Cancer Prevention and Research, Noida, India  
2Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India  
3Society for Life Sciences and Human Health, Allahabad, India

**CORRESPONDING AUTHOR**

Mausumi Bharadwaj, PhD, Division of Molecular Genetics and Biochemistry, Indian Council of Medical Research–National Institute of Cancer Prevention and Research, Sector 39, Noida, UP 201301, India; e-mail: mausumi.bharadwaj@gmail.com.

**AUTHOR CONTRIBUTIONS**

Conception and design: Richa Tripathi, Gayatri Rath, Mausumi Bharadwaj  
Collection and assembly of data: Richa Tripathi, Showket Hussain, Mausumi Bharadwaj  
Data analysis and interpretation: Richa Tripathi, Gayatri Rath, Showket Hussain, Vishwas Sharma, Shashi Sharma, Mausumi Bharadwaj, Ravi Mehrotra  
Manuscript writing: All authors  
Final approval of manuscript: All authors  
Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

No potential conflicts of interest were reported.

**SUPPORT**

Supported by Indian Council of Medical Research New Delhi Grant No. 3/1/3/PDF-2010/HRD-11/2nd batch.

**REFERENCES**

1. Liu J, Ye F, Chen H, et al: Expression of differentiation associated protein Hes1 and Hes5 in cervical squamous carcinoma and its precursors. Int J Gynecol Cancer 17:1293-1299, 2007  
2. Androussis-Theotokis A, Leiker RR, Soldner F, et al: Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 442:823-826, 2006  
3. Lu H, Jiang J, Gao Y: The cloning and activity of human Hes1 gene promoter. Mol Med Rep 17:659-665, 2016  
4. Hatakeyama J, Bessho Y, Kato K, et al: Hes genes regulate size, shape and histogenesis of the nervous system by control of the timing of neural stem cell differentiation. Development 131:5599-5609, 2004  
5. Liu ZH, Dai XM, Du B: Hes1: A key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther 16:353-359, 2015  
6. Liu J, Lu WG, Ye F, et al: Hes1/Hes5 gene inhibits differentiation via down-regulating Hash1 and promotes proliferation in cervical carcinoma cells. Int J Gynecol Cancer 20:1109-1116, 2010  
7. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
8. Sreedevi A, Javed R, Dinesh A: Epidemiology of cervical cancer with special focus on India. Int J Womens Health 7:405-414, 2015
9. Halim TA, Farooqi AA, Zaman F: Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int 13:61, 2013
10. Apgar BS, Zoschnick L, Wright TC Jr: The 2001 Bethesda System terminology. Am Fam Physician 68:1992-1998, 2003
11. Das BC, Hussain S, Nasare V, et al: Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 26:2669-2679, 2008
12. Shepherd JH: Cervical and vulva cancer: Changes in FIGO definitions of staging. Br J Obstet Gynaecol 103:405-406, 1996
13. Pirog EC: Cervical adenocarcinoma: Diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors. Arch Pathol Lab Med 141:1653-1667, 2017
14. Takeuchi S: Biology and treatment of cervical adenocarcinoma. Chin J Cancer Res 28:254-262, 2016
15. Veeraraghavalu K, Pett M, Kumar RV, et al: Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in JAGGED1 and manic fringe expression linked to notch activation. J Virol 78:8687-8700, 2004
16. Ramdass B, Malekal TT, Lakshmi S, et al: Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol 104:352-361, 2007
17. Rong C, Feng Y, Ye Z: Notch is a critical regulator in cervical cancer by regulating Numb splicing. Oncof Lett 13:2465-2470, 2017
18. Bahmassy AA, Zekri AR, Alam El-Din HM, et al: The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. J Egypt Natl Canc Inst 18:292-302, 2006
19. Tripathi R, Rath G, Jawanjal P, et al: Clinical impact of de-regulated Notch-1 and Notch-3 in the development and progression of HPV-associated different histological subtypes of precancerous and cancerous lesions of human uterine cervix. PLoS One 9:e98642, 2014
20. Kayyama R, Ohtsuka T, Kobayashi T: The Hes gene family: Repressors and oscillators that orchestrate embryogenesis. Development 134:1243-1251, 2007
21. Tripathi R, Rath G, Hussain S, et al: Jagged-1 induced molecular alterations in HPV associated invasive squamous cell and adenocarcinoma of the human uterine cervix. Sci Rep 8:9359, 2018
22. Kuncharin Y, Sangsphet N, Kueanjinda P, et al: MAML1 regulates cell viability via the NF-kB pathway in cervical cancer cell lines. Exp Cell Res 317:1830-1840, 2011